Stay updated with breaking news from Frederickb vivino. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Dazodalibep has successfully improved disease activity and symptoms two patient populations with Sjögren’s syndrome in a phase 2 trial, according to a press release from Horizon Therapeutics. The company added that dazodalibep (VIB4920, Horizon), a CD40 ligand antagonist, is currently the only drug in development to achieve the primary endpoint in these populations in a phase 2 trial. ....
The Company plans to work with the FDA to design a Phase 3 program in moderate-to-high systemic disease activity patients to begin in 2023, ahead of expectations - Horizon Therapeutics plc (Nasdaq: ....